Substitutions in SARS-CoV-2 Mpro Selected by Protease Inhibitor Boceprevir Confer Resistance to Nirmatrelvir

Nirmatrelvir, which targets the SARS-CoV-2 main protease (Mpro), is the first-in-line drug for prevention and treatment of severe COVID-19, and additional Mpro inhibitors are in development. However, the risk of resistance development threatens the future efficacy of such direct-acting antivirals. T...

Descripción completa

Detalles Bibliográficos
Autores principales: Gammeltoft, Karen Anbro, Zhou, Yuyong, Ryberg, Line Abildgaard, Pham, Long V., Binderup, Alekxander, Hernandez, Carlos Rene Duarte, Offersgaard, Anna, Fahnøe, Ulrik, Peters, Günther Herbert Johannes, Ramirez, Santseharay, Bukh, Jens, Gottwein, Judith Margarete
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10536901/
https://www.ncbi.nlm.nih.gov/pubmed/37766376
http://dx.doi.org/10.3390/v15091970

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10536901/
https://www.ncbi.nlm.nih.gov/pubmed/37766376
http://dx.doi.org/10.3390/v15091970

Ejemplares similares